<DOC>
	<DOCNO>NCT00005663</DOCNO>
	<brief_summary>The purpose study see valacyclovir ( Valtrex ) safe effective treatment ano-genital HSV infection ( herpes simplex virus infection anus external genitals ) HIV-infected patient .</brief_summary>
	<brief_title>A Study Valacyclovir Treatment Genital Herpes Simplex Virus HIV-Infected Patients</brief_title>
	<detailed_description>Patients randomize 2:1 ratio receive either Valtrex placebo , twice daily , 6 month . Patients come clinic routine monthly assessment 6 month , return clinic evaluation within 24 hour first sign symptom ano-genital HSV recurrence . Once clinician confirms presence least macular/papular lesion stage , double-blind suppressive therapy discontinue open-label treatment high dose Valtrex twice daily 5 day initiate . For first recurrence , patient instruct return clinic clinical assessment Day 5 recurrence . Patients heal Day 5 may offer additional five day open-label treatment , deem appropriate clinical investigator . If additional 5-day course open-label treatment medication dispense , patient return clinic Day 10 evaluation . Patients heal Day 10 manage deem appropriate investigator . Once treatment first ano-genital HSV recurrence complete patient heal , patient switch open-label suppressive therapy Valtrex remainder study period ( maximum 6 month ) . The total duration study patient 6 month .</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Herpes Simplex</mesh_term>
	<mesh_term>Herpes Genitalis</mesh_term>
	<mesh_term>Valacyclovir</mesh_term>
	<mesh_term>Acyclovir</mesh_term>
	<criteria>Inclusion Criteria Patients may eligible study : Are least 18 year old . Are HIVpositive . Have herpes simplex virus ( HSV ) 2 . Have receive combination antiHIV therapy least 2 month enter study . Have 4 recurrence anogenital HSV ( herpes infection anus genitals ) last 12 month . ( If patient take medication control HSV , he/she must 4 recurrence anogenital HSV per year begin regular antiHSV therapy , define therapy 12 week . ) Agree use effective method birth control 2 week take study drug , throughout study , 4 week complete study . ( A female may eligible able child . ) Exclusion Criteria Patients eligible study : Have blood vessel disease . Are sensitive acyclovir , Valtrex , famciclovir , ganciclovir . Are unable take medication mouth . Have nonhealed sore anus genitals begin study . Are use antiherpes drug . To eligible enrollment , patient currently use antiherpes drug must stop treatment drug begin study ; however , therapy may start investigator find necessary . Are use interferon . Patients receive interferon must stop interferon begin study . Have kidney liver problem . Are pregnant breastfeeding . Have type HSV resistant acyclovir , Valtrex , famciclovir , ganciclovir .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2001</verification_date>
	<keyword>Herpes Simplex</keyword>
	<keyword>Antiviral Agents</keyword>
	<keyword>Anus Diseases</keyword>
	<keyword>Herpes Genitalis</keyword>
	<keyword>Recurrence</keyword>
	<keyword>valacyclovir</keyword>
</DOC>